Long-term follow-up after 18 months of oral immunotherapy for peanut, egg, or milk allergy (5–15 years later)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study invites former participants from four OIT parent trials (PEAT, PrEMO, PPOIT-001, PPOIT-002) for a single clinic visit 5–15 years after finishing an 18-month OIT course. Visits include a blood draw for specific IgE, storage of plasma and PBMC for future research, a skin prick test, and allergy and quality-of-life questionnaires. The primary comparison is long-term health-related quality of life and allergy status in participants who achieved remission versus those who did not. Eligibility requires prior participation in one of the listed parent trials and receipt of at least one OIT dose.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Previous participant of PEAT, PrEMO, PPOIT-001 or PPOIT-002 parent study
* Received at least one dose of OIT treatment in the parent study
* Written informed consent from participant and/or parent/guardian (if below 18 years of age)

Exclusion Criteria:

-Have any conditions that, in the opinion of the investigator, precludes participation for reason of safety

Where it's running

• Murdoch Children's Research Institute
  Parkville, Victoria, Australia Recruiting

Study contacts

• Principal investigator: Adriana Chebar Lozinsky Rolnik — Murdoch Childrens Research Institute
• Study coordinator: Adriana Chebar Lozinsky Rolnik
• Email: lpem.study@mcri.edu.au
• Phone: 61399366435

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rush versus conventional oral immunotherapy for cow's milk and hen's egg allergy in children

  This test compares a faster 'rush' oral immunotherapy schedule with a conventional slower schedule to see which better helps children aged 6–16 with milk or egg allergy tolerate those foods.

  Recruiting Phase 2/3 Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Madrid · NCT06976775

• Remibrutinib for IgE-mediated peanut, milk, and egg allergy

  This study tests whether remibrutinib can help people with peanut, milk, or egg allergies by comparing it to placebo over 52 weeks.

  Recruiting at 22 sites Phase 3 Novartis · Birmingham, Alabama and 21 other locations · NCT07768371

• LCA-0061 dose-ranging safety study for people with allergies

  This Phase 1 study tests whether different single and multiple doses of LCA-0061 are safe and tolerable in people with atopy or peanut allergy, compared with placebo.

  Recruiting Phase 1 Lycia Therapeutics, Inc. · Mississauga, Ontario · NCT07701954

• MY006 to prevent severe allergic reactions from peanut exposure

  MY006 injections will be tested to see if they prevent severe allergic reactions in adults and adolescents with peanut allergy.

  Recruiting at 8 sites Phase 1 Mabylon AG · Little Rock, Arkansas and 8 other locations · NCT07287033

• Home-based food challenges for adults with food allergies

  This study is testing if it's safe and practical for adults with certain food allergies to try eating those foods at home instead of in a clinic.

  Recruiting at 2 sites Austin Health · Melbourne, Victoria and 1 other locations · NCT06916819

• Maternal peanut and egg consumption versus avoidance during pregnancy and breastfeeding

  This study will test whether mothers eating or avoiding peanuts and eggs from late pregnancy through breastfeeding changes babies' chances of developing peanut or egg allergies.

  Recruiting University of Rochester · Rochester, New York · NCT06260956

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.